Oral Treatment with the D-enantiomeric Peptide D3 Improves the Pathology and Behavior of Alzheimer's Disease Transgenic Mice

Overview

Journal ACS Chem Neurosci

Publisher American Chemical Society

Specialty Neurology

Date 2012 Jul 11

PMID 22778851

Citations 44

Authors

Susanne Aileen Funke

Thomas van Groen

Inga Kadish

Dirk Bartnik

Luitgard Nagel-Steger

Oleksandr Brener

Torsten Sehl

Renu Batra-Safferling

Christine Moriscot

Guy Schoehn

Anselm H C Horn

Andreas Muller-Schiffmann

Carsten Korth

Heinrich Sticht

Dieter Willbold

Affiliations

Soon will be listed here.

Abstract

Several lines of evidence suggest that the amyloid-β-peptide (Aβ) plays a central role in the pathogenesis of Alzheimer's disease (AD). Not only Aβ fibrils but also small soluble Aβ oligomers in particular are suspected to be the major toxic species responsible for disease development and progression. The present study reports on in vitro and in vivo properties of the Aβ targeting d-enantiomeric amino acid peptide D3. We show that next to plaque load and inflammation reduction, oral application of the peptide improved the cognitive performance of AD transgenic mice. In addition, we provide in vitro data elucidating the potential mechanism underlying the observed in vivo activity of D3. These data suggest that D3 precipitates toxic Aβ species and converts them into nonamyloidogenic, nonfibrillar, and nontoxic aggregates without increasing the concentration of monomeric Aβ. Thus, D3 exerts an interesting and novel mechanism of action that abolishes toxic Aβ oligomers and thereby supports their decisive role in AD development and progression.

Citing Articles

A novel peptide-based tau aggregation inhibitor as a potential therapeutic for Alzheimer's disease and other tauopathies.

Aggidis A, Devitt G, Zhang Y, Chatterjee S, Townsend D, Fullwood N Alzheimers Dement. 2024; 20(11):7788-7804.

PMID: 39360630 PMC: 11567856. DOI: 10.1002/alz.14246.

Phage Display Technology in Biomarker Identification with Emphasis on Non-Cancerous Diseases.

Sadraeian M, Maleki R, Moraghebi M, Bahrami A Molecules. 2024; 29(13).

PMID: 38998954 PMC: 11243120. DOI: 10.3390/molecules29133002.

Tau- and α-synuclein-targeted gold nanoparticles: applications, opportunities, and future outlooks in the diagnosis and therapy of neurodegenerative diseases.

Tapia-Arellano A, Cabrera P, Cortes-Adasme E, Riveros A, Hassan N, Kogan M J Nanobiotechnology. 2024; 22(1):248.

PMID: 38741193 PMC: 11092257. DOI: 10.1186/s12951-024-02526-0.

Advances in Alzheimer's Disease-Associated Aβ Therapy Based on Peptide.

Wang C, Shao S, Li N, Zhang Z, Zhang H, Liu B Int J Mol Sci. 2023; 24(17).

PMID: 37685916 PMC: 10487952. DOI: 10.3390/ijms241713110.

From Small Peptides to Large Proteins against Alzheimer'sDisease.

Picone P, Sanfilippo T, Vasto S, Baldassano S, Guggino R, Nuzzo D Biomolecules. 2022; 12(10).

PMID: 36291553 PMC: 9599460. DOI: 10.3390/biom12101344.

References

Jakob-Roetne R, Jacobsen H . Alzheimer's disease: from pathology to therapeutic approaches. Angew Chem Int Ed Engl. 2009; 48(17):3030-59. DOI: 10.1002/anie.200802808. View

Price K, Crouch P, White A . Therapeutic treatment of Alzheimer's disease using metal complexing agents. Recent Pat CNS Drug Discov. 2008; 2(3):180-7. DOI: 10.2174/157488907782411774. View

Lambert M, Barlow A, Chromy B, Edwards C, Freed R, Liosatos M . Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A. 1998; 95(11):6448-53. PMC: 27787. DOI: 10.1073/pnas.95.11.6448. View

Klunk W, Jacob R, Mason R . Quantifying amyloid beta-peptide (Abeta) aggregation using the Congo red-Abeta (CR-abeta) spectrophotometric assay. Anal Biochem. 1999; 266(1):66-76. DOI: 10.1006/abio.1998.2933. View

Juhasz G, Marki A, Vass G, Fulop L, Budai D, Penke B . An intraperitoneally administered pentapeptide protects against Abeta (1-42) induced neuronal excitation in vivo. J Alzheimers Dis. 2009; 16(1):189-96. DOI: 10.3233/JAD-2009-0947. View

Poduslo J, Curran G, Kumar A, Frangione B, Soto C . Beta-sheet breaker peptide inhibitor of Alzheimer's amyloidogenesis with increased blood-brain barrier permeability and resistance to proteolytic degradation in plasma. J Neurobiol. 1999; 39(3):371-82. View

Hardy J, Higgins G . Alzheimer's disease: the amyloid cascade hypothesis. Science. 1992; 256(5054):184-5. DOI: 10.1126/science.1566067. View

van Groen T, Kadish I, Wiesehan K, Funke S, Willbold D . In vitro and in vivo staining characteristics of small, fluorescent, Abeta42-binding D-enantiomeric peptides in transgenic AD mouse models. ChemMedChem. 2008; 4(2):276-82. DOI: 10.1002/cmdc.200800289. View

Wiesehan K, Buder K, Linke R, Patt S, Stoldt M, Unger E . Selection of D-amino-acid peptides that bind to Alzheimer's disease amyloid peptide abeta1-42 by mirror image phage display. Chembiochem. 2003; 4(8):748-53. DOI: 10.1002/cbic.200300631. View

10.

Haass C, Selkoe D . Cellular processing of beta-amyloid precursor protein and the genesis of amyloid beta-peptide. Cell. 1993; 75(6):1039-42. DOI: 10.1016/0092-8674(93)90312-e. View

11.

Nerelius C, Johansson J, Sandegren A . Amyloid beta-peptide aggregation. What does it result in and how can it be prevented?. Front Biosci (Landmark Ed). 2009; 14(5):1716-29. DOI: 10.2741/3335. View

12.

Wiesehan K, Stohr J, Nagel-Steger L, van Groen T, Riesner D, Willbold D . Inhibition of cytotoxicity and amyloid fibril formation by a D-amino acid peptide that specifically binds to Alzheimer's disease amyloid peptide. Protein Eng Des Sel. 2008; 21(4):241-6. DOI: 10.1093/protein/gzm054. View

13.

Tjernberg L, Naslund J, Lindqvist F, Johansson J, Karlstrom A, Thyberg J . Arrest of beta-amyloid fibril formation by a pentapeptide ligand. J Biol Chem. 1996; 271(15):8545-8. DOI: 10.1074/jbc.271.15.8545. View

14.

Kang J, Lemaire H, Unterbeck A, Salbaum J, Masters C, Grzeschik K . The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature. 1987; 325(6106):733-6. DOI: 10.1038/325733a0. View

15.

Liu H, Funke S, Willbold D . Transport of Alzheimer disease amyloid-beta-binding D-amino acid peptides across an in vitro blood-brain barrier model. Rejuvenation Res. 2009; 13(2-3):210-3. DOI: 10.1089/rej.2009.0926. View

16.

Roberson E, Mucke L . 100 years and counting: prospects for defeating Alzheimer's disease. Science. 2006; 314(5800):781-4. PMC: 3544944. DOI: 10.1126/science.1132813. View

17.

Bieschke J, Russ J, Friedrich R, Ehrnhoefer D, Wobst H, Neugebauer K . EGCG remodels mature alpha-synuclein and amyloid-beta fibrils and reduces cellular toxicity. Proc Natl Acad Sci U S A. 2010; 107(17):7710-5. PMC: 2867908. DOI: 10.1073/pnas.0910723107. View

18.

Eisele Y, Bolmont T, Heikenwalder M, Langer F, Jacobson L, Yan Z . Induction of cerebral beta-amyloidosis: intracerebral versus systemic Abeta inoculation. Proc Natl Acad Sci U S A. 2009; 106(31):12926-31. PMC: 2722323. DOI: 10.1073/pnas.0903200106. View

19.

Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi H . Forecasting the global burden of Alzheimer's disease. Alzheimers Dement. 2009; 3(3):186-91. DOI: 10.1016/j.jalz.2007.04.381. View

20.

Kassler K, Horn A, Sticht H . Effect of pathogenic mutations on the structure and dynamics of Alzheimer's A beta 42-amyloid oligomers. J Mol Model. 2009; 16(5):1011-20. DOI: 10.1007/s00894-009-0611-1. View